NCT03429127

Brief Summary

The purpose of this study was to investigate whether the balanced fluids therapy change plasma osmolality in neurosurgical procedures due to brain tumors, meningeomas and arterio-venous malformation.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
120

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Mar 2017

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 23, 2017

Completed
11 months until next milestone

First Submitted

Initial submission to the registry

February 3, 2018

Completed
9 days until next milestone

First Posted

Study publicly available on registry

February 12, 2018

Completed
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 23, 2019

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

February 23, 2020

Completed
Last Updated

April 18, 2019

Status Verified

April 1, 2019

Enrollment Period

2.6 years

First QC Date

February 3, 2018

Last Update Submit

April 16, 2019

Conditions

Keywords

balanced fluids, neurosurgery, plasma osmolality

Outcome Measures

Primary Outcomes (1)

  • Changes in acid base pH status

    Changes in acid base pH status after each 500 ml of normal saline vrs. balanced fluid

    During operation and immediately after operation

Secondary Outcomes (1)

  • Changes in electrolytes (sodium and chloride)

    During operation and immediately after operation

Other Outcomes (1)

  • Plasma osmolality

    Immediately after operation

Study Arms (2)

Normal saline fluid group

The patients in this group will receive up to 2000 ml of normal saline during neurosurgical operation.

Other: Normal saline

Balanced fluid group

The patients in this group will receive up to 2000 ml of balanced fluids during neurosurgical operation.

Other: Balanced fluid

Interventions

Plasma osmolality, acid base status and electrolytes after application up to 2000 ml of normal saline during neurosurgical operation

Also known as: 0,9 % sodium chloride
Normal saline fluid group

Plasma osmolality, acid base status and electrolytes after application of up to 2000 ml balanced fluids during neurosurgical operation

Also known as: Plasma-Lyte 148
Balanced fluid group

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patients who underwent neurosurgical procedure because of brain tumor, meningeoma and vascular malformation. And without signs of elevated intracranial pressure and any history of kidney or heart disease.

You may qualify if:

  • Patients with brain tumor, meningeomas and vascular malformation.

You may not qualify if:

  • Patients with signs of elevated intracranial pressure; History of kidney disease, History of heart disease

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

UHC Zgagreb

Zagreb, 10000, Croatia

RECRUITING

MeSH Terms

Conditions

NeoplasmsCentral Nervous System Vascular Malformations

Interventions

Saline SolutionPlasma-lyte 148

Condition Hierarchy (Ancestors)

Nervous System MalformationsNervous System DiseasesVascular MalformationsCardiovascular AbnormalitiesCardiovascular DiseasesCongenital AbnormalitiesCongenital, Hereditary, and Neonatal Diseases and Abnormalities

Intervention Hierarchy (Ancestors)

Crystalloid SolutionsIsotonic SolutionsSolutionsPharmaceutical Preparations

Study Officials

  • Natasa Kovac, M.D.

    UHC Zagreb

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Natasa Kovac, M.D.

CONTACT

Inga Mladic Batinica, M.D.

CONTACT

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Natasa Kovac, M.D., Anesthesiologyst and intensive care medicine subspecialist

Study Record Dates

First Submitted

February 3, 2018

First Posted

February 12, 2018

Study Start

March 23, 2017

Primary Completion

October 23, 2019

Study Completion

February 23, 2020

Last Updated

April 18, 2019

Record last verified: 2019-04

Data Sharing

IPD Sharing
Will not share

Locations